Global Sickle Cell Disease Treatment Market 2019-2023

鎌状赤血球病治療の世界市場2019-2023

◆タイトル:Global Sickle Cell Disease Treatment Market 2019-2023
◆商品コード:IRTNTR30672
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2019年1月16日
◆ページ数:113
◆資料形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル、アジア、北米、ヨーロッパ(EMEA)
◆産業分野:医療・バイオ
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥267,500見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥321,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥428,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

当調査レポートでは、鎌状赤血球病治療の世界市場について調査・分析し、市場概要、市場環境、鎌状赤血球病治療市場規模、疾患別(鎌状赤血球貧血、鎌状赤血球サラセミア)分析、市場動向、競争環境、主要地域別市場規模(北米、ヨーロッパ、アジアなど)、関連企業情報などを含め、以下の構成でお届け致します。
・エグゼクティブサマリー
・調査範囲・調査手法
・鎌状赤血球病治療の世界市場概要
・鎌状赤血球病治療の世界市場環境
・鎌状赤血球病治療の世界市場動向
・鎌状赤血球病治療の世界市場規模
・鎌状赤血球病治療の世界市場:業界構造分析
・鎌状赤血球病治療の世界市場:疾患別(鎌状赤血球貧血、鎌状赤血球サラセミア)
・鎌状赤血球病治療の世界市場:地域別市場規模・分析
・鎌状赤血球病治療の北米市場規模・予測
・鎌状赤血球病治療のヨーロッパ・中東・アフリカ市場規模・予測
・鎌状赤血球病治療のアジア太平洋市場規模・予測
・鎌状赤血球病治療の主要国分析
・鎌状赤血球病治療の世界市場:意思決定フレームワーク
・鎌状赤血球病治療の世界市場:成長要因、課題
・鎌状赤血球病治療の世界市場:競争環境
・鎌状赤血球病治療の世界市場:関連企業情報(ベンダー分析)

About this market
Strong pipeline of drugs to drive market growth. The pipeline for sickle cell disease comprises strong pharmaceutical companies with novel therapies in the late stages of clinical trials and various mid and small pharmaceutical companies with early-stage pipeline drugs. The strong efficacy of these drugs in the early stages of clinical trials has led to a positive opinion from the regulatory bodies. Thus, helping the vendors with quick development of these drugs. Technavio’s analysts have predicted that the sickle cell disease treatment market will register a CAGR of over 11% by 2023.
Market Overview
High prevalence of sickle cell disease
The global sickle cell disease treatment market has witnessed a significant increase in the number of cases of sickle cell diseases in recent years. For instance, according to the CDC. in 2017, sickle cell diseases affected approximately 100,000 Americans. While it is rather rare in Hispanic-Americans and Asian-Americans, the disease is more common in African-Americans, with the prevalence being as high as one per every 365 people.
Lack of approved therapies
Despite blood transfusion being heavily used to treat sickle cell diseases, the market faces a major challenge from the lack of approved therapies. Currently, the market has only three approved therapies for sickle cell diseases, and six molecules are in Phase Ill of clinical trials.
For the detailed list of factors that will drive and challenge the growth of the sickle cell disease treatment market during the 2019-2023, view our report.
Competitive Landscape
The market appears to be fragmented and with the presence of several companies including Novartis and Pfizer the competitive environment is quite intense. Factors such as the high prevalence of sickle cell disease and the strong pipeline of drugs, will provide considerable growth opportunities to sickle cell disease treatment manufactures. ADDMEDICA, Bristol-Myers Squibb, Emmaus Medical, Novartis, and Pfizer are some of the major companies covered in this report.

【資料の目次】

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
• 2.1 Preface
• 2.2 Preface
• 2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 04: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 06: MARKET SEGMENTATION BY INDICATION
• Market segmentation by indication
• Comparison by indication
• Sickle cell anemia – Market size and forecast 2018-2023
• Sickle beta thalassemia – Market size and forecast 2018-2023
• Others – Market size and forecast 2018-2023
• Market opportunity by indication
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• North America – Market size and forecast 2018-2023
• Europe – Market size and forecast 2018-2023
• Asia – Market size and forecast 2018-2023
• ROW – Market size and forecast 2018-2023
• Key leading countries
• Market opportunity
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 11: MARKET TRENDS
PART 12: VENDOR LANDSCAPE
• Overview
• Landscape disruption
• Competitive scenario
PART 13: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• ADDMEDICA
• Bristol-Myers Squibb
• Emmaus Medical
• Novartis
• Pfizer
PART 14: APPENDIX
• Research methodology
• List of abbreviations
PART 15: EXPLORE TECHNAVIO

Exhibit 01: Global pharmaceuticals market
Exhibit 02: Segments of global pharmaceuticals market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition – Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition – Five forces 2018
Exhibit 17: Indication – Market share 2018-2023 (%)
Exhibit 18: Comparison by indication
Exhibit 19: Sickle cell anemia – Market size and forecast 2018-2023 ($ millions)
Exhibit 20: Sickle cell anemia – Year-over-year growth 2019-2023 (%)
Exhibit 21: Sickle beta thalassemia – Market size and forecast 2018-2023 ($ millions)
Exhibit 22: Sickle beta thalassemia – Year-over-year growth 2019-2023 (%)
Exhibit 23: Others – Market size and forecast 2018-2023 ($ millions)
Exhibit 24: Others – Year-over-year growth 2019-2023 (%)
Exhibit 25: Market opportunity by indication
Exhibit 26: Customer landscape
Exhibit 27: Market share by geography 2018-2023 (%)
Exhibit 28: Geographic comparison
Exhibit 29: North America – Market size and forecast 2018-2023 ($ millions)
Exhibit 30: North America – Year-over-year growth 2019-2023 (%)
Exhibit 31: Europe – Market size and forecast 2018-2023 ($ millions)
Exhibit 32: Europe – Year-over-year growth 2019-2023 (%)
Exhibit 33: Asia – Market size and forecast 2018-2023 ($ millions)
Exhibit 34: Asia – Year-over-year growth 2019-2023 (%)
Exhibit 35: ROW – Market size and forecast 2018-2023 ($ millions)
Exhibit 36: ROW – Year-over-year growth 2019-2023 (%)
Exhibit 37: Key leading countries
Exhibit 38: Market opportunity
Exhibit 39: Impact of drivers and challenges
Exhibit 40: Gene therapy pipeline for sickle cell
Exhibit 41: Vendor landscape
Exhibit 42: Landscape disruption
Exhibit 43: Vendors covered
Exhibit 44: Vendor classification
Exhibit 45: Market positioning of vendors
Exhibit 46: ADDMEDICA – Vendor overview
Exhibit 47: ADDMEDICA – Business segments
Exhibit 48: ADDMEDICA – Organizational developments
Exhibit 49: ADDMEDICA – Key offerings
Exhibit 50: ADDMEDICA – Key customers
Exhibit 51: Bristol-Myers Squibb – Vendor overview
Exhibit 52: Bristol-Myers Squibb – Business segments
Exhibit 53: Bristol-Myers Squibb – Organizational developments
Exhibit 54: Bristol-Myers Squibb – Geographic focus
Exhibit 55: Bristol-Myers Squibb – Key offerings
Exhibit 56: Bristol-Myers Squibb – Key customers
Exhibit 57: Emmaus Medical – Vendor overview
Exhibit 58: Emmaus Medical – Business segments
Exhibit 59: Emmaus Medical – Organizational developments
Exhibit 60: Emmaus Medical – Geographic focus
Exhibit 61: Emmaus Medical – Key offerings
Exhibit 62: Emmaus Medical – Key customers
Exhibit 63: Novartis – Vendor overview
Exhibit 64: Novartis – Business segments
Exhibit 65: Novartis – Organizational developments
Exhibit 66: Novartis – Geographic focus
Exhibit 67: Novartis – Segment focus
Exhibit 68: Novartis – Key offerings
Exhibit 69: Novartis – Key customers
Exhibit 70: Pfizer – Vendor overview
Exhibit 71: Pfizer – Business segments
Exhibit 72: Pfizer – Organizational developments
Exhibit 73: Pfizer – Geographic focus
Exhibit 74: Pfizer – Segment focus
Exhibit 75: Pfizer – Key offerings
Exhibit 76: Pfizer – Key customers




【掲載企業】

ADDMEDICA、Bristol-Myers Squibb、Emmaus Medical、Novartis、and Pfizer

★調査レポート[鎌状赤血球病治療の世界市場2019-2023] (Global Sickle Cell Disease Treatment Market 2019-2023 / IRTNTR30672)販売に関する免責事項
[鎌状赤血球病治療の世界市場2019-2023] (Global Sickle Cell Disease Treatment Market 2019-2023 / IRTNTR30672)についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆